secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0000105770-25-000090
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q3 net sales $804.6M (+7.7%), adjusted EPS $1.96; raises FY guidance
--------------------------------------------------------------------------------

- Proprietary Products HVP Components net sales $390M, +16.3% YoY, driven by GLP-1 products and HVP conversion.
- Full-year 2025 net sales guidance raised to $3.060-3.070B; adjusted EPS guidance raised to $7.06-7.11.
- Q4 2025 guidance: net sales $790-800M, adjusted diluted EPS $1.81-1.86.
- Free cash flow nine months $293.9M, +53.7% YoY; repurchased 552,593 shares for $134.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/0000105770-25-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/wst-20251023.htm
  HTML page:      https://secwatch.observer/filing/0000105770-25-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer